Lumida
/RCKT
⌘K
Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

RCKT
$3.63USD↓-2.16%-0.08 today

MARKET CAP

398.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $4

52W RANGE

$3
$5

AI Summary

Stalk
StalkMedium

RCKT is in a Stage 2 advance after clearing the 3.55 resistance on strong volume. Price is now extended above rising EMAs with extreme overbought readings on RSI and Options Score. While the medium-term trend remains bullish following the Momentum Breakout, timing is unfavorable until a pullback into the 9/21 EMA zone and prior breakout level near 3.55 offers cleaner entry.

  • ↑Anticipated resumption of Danon disease trial after FDA alignment
  • ↑Low-dose cohort showed NYHA class improvements, advancing to Phase 2
  • ↓Negative earnings yield and poor profitability raise operational sustainability concerns
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a clinical-stage biopharmaceutical company specializing in transformative gene therapy solutions aimed at treating rare diseases, particularly genetic disorders such as Danon disease and Fanconi anemia. The company is leveraging a proprietary lentiviral platform to develop long-lasting therapies, positioning itself as a leader in the fast-growing gene therapy market – an area that remains increasingly critical as it addresses significant unmet medical needs.

Bull says

  • ↑Anticipated resumption of Danon disease trial after FDA alignment
  • ↑Low-dose cohort showed NYHA class improvements, advancing to Phase 2
  • ↑Rare pediatric voucher sale for $180M drove Q2 net income of $123.2M
  • ↑Over 20 patients registered interest, ensuring robust trial enrollment
  • ↑Strong institutional support indicated by elevated 13F ownership levels
  • ↑Modest book-to-price ratio may attract value-focused investors

Bear says

  • ↓Negative earnings yield and poor profitability raise operational sustainability concerns
  • ↓Analysts cut price target to $15 on worsening earnings revisions
  • ↓Ongoing FDA reviews and protocol modifications risk trial timeline delays
  • ↓Elevated volatility suggests potential for extreme price swings
  • ↓Narrowed dosing criteria may limit addressable patient pool and revenue
  • ↓Pessimistic analyst sentiment and declining revisions signal further downside

Investment themes with RCKT

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q3 2021 · Mgmt. Guidance

Updated 08-17-2026bullish

Transcript signals

Bull points

  • Rocket has had extraordinary growth since going public.
  • The company has already delivered a lot of value to shareholders.
  • And I look forward to seeing Rocket's continued success in the future over the long term.

Bear points

  • we are deeply saddened that the first patient treated in our infantile malignant osteocatrosis phase one trial has passed away from likely non-gene therapy related pulmonary complications with autopsy confirmed evidence of pulmonary hemorrhage
Read full transcript analysis ›